ID

15502

Descripción

Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00151086

Link

https://clinicaltrials.gov/show/NCT00151086

Palabras clave

  1. 1/6/16 1/6/16 -
Subido en

1 de junio de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Prostate Cancer NCT00151086

Eligibility Prostate Cancer NCT00151086

Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI-1
C1512693
patients must have a histologic diagnosis of adenocarcinoma of the prostate. (no evidence of brain metastasis or untreated spinal cord compression.)
Descripción

adenocarcinoma of the prostate

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0600139
patients on total androgen suppression therapy must undergo nonsteroidal antiandrogen withdrawal and demonstrate at rising psa (prostate specific antigen) 4 weeks after withdrawal for flutamide and 6 weeks after withdrawal for bicalutamide or nilutamide.
Descripción

androgen suppression therapy

Tipo de datos

boolean

patients must have measurable soft tissue disease or evaluable (abnormal bone scan and/or elevated psa). if psa is the only evidence of progressive disease it must be greater than or equal to 4ng/ml.
Descripción

measurable soft tissue disease

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0263978
UMLS CUI [1,2]
C1513041
adequate bone marrow, renal and liver function
Descripción

bone marrow renal and liver function

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0005953
UMLS CUI [2]
C0232804
UMLS CUI [3]
C0232741
ecog (eastern cooperative oncology group) performance status of 0-2 (a measure of general well being on a scale of 0-5 where 0 represents asymptomatic and 5 represents death)
Descripción

ecog

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
must be at least 18 years of age
Descripción

age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
must have a life expectancy of greater than or equal to 12 weeks
Descripción

life expectancy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023671
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI-1
C0680251
have previously received vinca alkaloid-based cytotoxic chemotherapy or radiation to greater than or equal to 50% of the total bone marrow.
Descripción

vinca alkaloid-based cytotoxic chemotherapy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0042672
UMLS CUI [1,2]
C0392920
UMLS CUI [2]
C1522449
evidence of brain metastasis
Descripción

brain metastasis

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0220650
spinal cord compression
Descripción

spinal cord compression

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0037926
prior malignancy except for in situ carcinoma, nonmelanoma skin cancer, or adequately treated malignancy that has been inactive for less than 3 years
Descripción

prior malignancy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0006826
patients with preexisting neuropathy of greater than or equal to grade 2
Descripción

preexisting neuropathy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0442874
active gastrointestinal disease, or a disorder that alters gastrointestinal motility or absorption
Descripción

active gastrointestinal disease

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0017178

Similar models

Eligibility Prostate Cancer NCT00151086

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Inclusion Criteria
C1512693 (UMLS CUI-1)
adenocarcinoma of the prostate
Item
patients must have a histologic diagnosis of adenocarcinoma of the prostate. (no evidence of brain metastasis or untreated spinal cord compression.)
boolean
C0600139 (UMLS CUI [1])
androgen suppression therapy
Item
patients on total androgen suppression therapy must undergo nonsteroidal antiandrogen withdrawal and demonstrate at rising psa (prostate specific antigen) 4 weeks after withdrawal for flutamide and 6 weeks after withdrawal for bicalutamide or nilutamide.
boolean
measurable soft tissue disease
Item
patients must have measurable soft tissue disease or evaluable (abnormal bone scan and/or elevated psa). if psa is the only evidence of progressive disease it must be greater than or equal to 4ng/ml.
boolean
C0263978 (UMLS CUI [1,1])
C1513041 (UMLS CUI [1,2])
bone marrow renal and liver function
Item
adequate bone marrow, renal and liver function
boolean
C0005953 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
ecog
Item
ecog (eastern cooperative oncology group) performance status of 0-2 (a measure of general well being on a scale of 0-5 where 0 represents asymptomatic and 5 represents death)
boolean
C1520224 (UMLS CUI [1])
age
Item
must be at least 18 years of age
boolean
C0001779 (UMLS CUI [1])
life expectancy
Item
must have a life expectancy of greater than or equal to 12 weeks
boolean
C0023671 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI-1)
vinca alkaloid-based cytotoxic chemotherapy
Item
have previously received vinca alkaloid-based cytotoxic chemotherapy or radiation to greater than or equal to 50% of the total bone marrow.
boolean
C0042672 (UMLS CUI [1,1])
C0392920 (UMLS CUI [1,2])
C1522449 (UMLS CUI [2])
brain metastasis
Item
evidence of brain metastasis
boolean
C0220650 (UMLS CUI [1])
spinal cord compression
Item
spinal cord compression
boolean
C0037926 (UMLS CUI [1])
prior malignancy
Item
prior malignancy except for in situ carcinoma, nonmelanoma skin cancer, or adequately treated malignancy that has been inactive for less than 3 years
boolean
C0006826 (UMLS CUI [1])
preexisting neuropathy
Item
patients with preexisting neuropathy of greater than or equal to grade 2
boolean
C0442874 (UMLS CUI [1])
active gastrointestinal disease
Item
active gastrointestinal disease, or a disorder that alters gastrointestinal motility or absorption
boolean
C0017178 (UMLS CUI [1])

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial